Long-term therapy with inhaled iloprost in patients with pulmonary hypertension

• Verfasst von: Olschewski, Horst [VerfasserIn]
• Verfasst von: Hoeper, Marius M. [VerfasserIn]
• Verfasst von: Behr, Juergen [VerfasserIn]
• Verfasst von: Ewert, Ralf [VerfasserIn]
• Verfasst von: Meyer, Andreas [VerfasserIn]
• Verfasst von: Borst, Mathias M. [VerfasserIn]
• Verfasst von: Winkler, Jörg [VerfasserIn]
• Verfasst von: Pfeifer, Michael [VerfasserIn]
• Verfasst von: Wilkens, Heinrike [VerfasserIn]
• Verfasst von: Ghofrani, Hossein Ardeschir [VerfasserIn]
• Verfasst von: Nikkho, Sylvia [VerfasserIn]
• Verfasst von: Seeger, Werner [VerfasserIn]
• Titel: Long-term therapy with inhaled iloprost in patients with pulmonary hypertension
• Verf.angabe: Horst Olschewski, Marius M. Hoeper, Juergen Behr, Ralf Ewert, Andreas Meyer, Mathias M. Borst, Jörg Winkler, Michael Pfeifer, Heinrike Wilkens, Hossein Ardeschir Ghofrani, Sylvia Nikkho, Werner Seeger
• E-Jahr: 2010
• Jahr: 11 February 201
• Umfang: 10 S.
• Fussnoten: Gesehen am 14.06.2023
• Titel Quelle: Enthalten in: Respiratory medicine
• Ort Quelle: Burlington, Mass. : Harcourt, 1999
• Jahr Quelle: 2010
• Band/Heft Quelle: 104(2010), 5 vom: Mai, Seite 731-740
• ISSN Quelle: 1532-3064
• DOI: doi:10.1016/j.rmed.2010.01.008
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Hypertension
• Sach-SW: Inhaled iloprost
• Sach-SW: Long-term treatment
• Sach-SW: pulmonary
• Sach-SW: Pulmonary arterial hypertension
• Sach-SW: Survival
• K10plus-PPN: 1848964862

Abstract

Aims - To investigate the long-term safety of inhaled iloprost in patients with pulmonary hypertension (pH), including idiopathic PAH (IPAH group) and other forms of pulmonary hypertension (PHother). - Methods and results - Sixty-three patients (IPAH group, n=40, PHother n=23) were enrolled to receive inhaled iloprost either from baseline or after 3 months in a prospective, open-label 2-year study. Iloprost was inhaled 6-9 times daily with a night pause employing a jet nebulizer delivering an inhaled single dose of 4μg at the mouthpiece. In the case of side effects the single dose was reduced to 2μg. Sixty patients received at least 1 dose of inhaled iloprost. Thirty-six patients completed at least 630 days of therapy (25 IPAH, 11 PHother), 19 patients dropped out prematurely and 8 patients died (3 IPAH, 5 PHother). There were no drug-induced toxicities and only mild to moderate side effects. The most common side effects were coughing and flushing. Two-year survival was estimated at 85% (IPAH group 91%, PHother 78%). A modified analysis was performed to correct for differential drop-out. It included follow-up data from the premature discontinuations and revealed a 2-year survival of 87% [95% CI, 76%-98%] in the IPAH group while the predicted survival was 63%. The iloprost dose increased by 16% over 2 years. - Conclusion - Inhaled iloprost is well tolerated as long-term therapy and no substantial dose increase is required. Although uncontrolled, the data suggest a long-term clinical benefit from continued therapy with inhaled iloprost.